Prognostic implications of chemotherapy-induced neutropenia in stage III colorectal cancer

Background: Previous studies have reported chemotherapy-induced neutropenia (CIN) as a prognostic factor in stage IV colorectal cancer (CRC). However, only few reports analyzed the prognostic value of CIN in patients with stage III CRC who received adjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX). We aimed to investigate the prognostic implications of CIN in patients with stage III CRC who received adjuvant chemotherapy with FOLFOX. Materials and methods: We retrospectively analyzed patients with stage III CRC who received adjuvant chemotherapy with FOLFOX at a tertiary hospital between January 2007 and December 2017. Severe CIN was defined as an absolute neutrophil count of less than 1000/mm(3). Three-y disease-free survival (DFS) and overall survival (OS) were analyzed as primary end-points. Results: Among the 199 patients included in this study, 110 patients (55.3%) experienced severe CIN. There were no significant differences in survival outcomes between the control and CIN groups (control group versus CIN group: 3-y OS, 82.0 % versus 72.7 %; log rank, P = 0.250 and 3-y DFS, 71.9 % versus 62.7; log rank, P = 0.294). Univariate and multivariate analyses revealed that CIN did not affect DFS and OS in patients with stage III CRC who received adjuvant FOLFOX chemotherapy. Conclusions: Severe CIN occurring during adjuvant FOLFOX chemotherapy did not play a significant role in the prognosis of patients with stage III CRC. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

This study investigated the prognostic implications of severe chemotherapy-induced neutropenia (CIN) in patients with stage III colorectal cancer (CRC) who received adjuvant FOLFOX chemotherapy. Results showed that severe CIN did not significantly impact the survival outcomes of patients with stage III CRC.